eltrombopag and romiplastim
PreclinicalProtein / enzyme
eltrombopag and romiplastim is one of 25 small molecule programs targeting Thrombocytopenic Purpura. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
47 competitors in Thrombocytopenic Purpura
#DrugCompanyPhaseTrials
1Promacta
GSKPhase 3
Rayos
RRoxane Laboratories
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Doptelet
AAkarx
Phase 3
Igpro10
CSL BehringApproved
Rituxan
RochePhase 2
AMG 531
AmgenPhase 3
Fostamatinib Bid
RRigel Pharmaceuticals
Phase 3
Immunoglobulin
SanofiPhase 2
Doxil
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thrombocytopenic Purpura1 trial
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
Not yet recruiting·—··NCT06137105·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for eltrombopag and romiplastim. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company
- AAssiut University